This article is more than 5 years old. Information may no longer be current.

B&L to co-promote Retisert with Novartis

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ROCHESTER, N.Y. — Retisert, Bausch & Lomb’s implant for the treatment of chronic noninfectious posterior segment uveitis, will now be co-promoted in the United States by B&L and Novartis Ophthalmics, according to a press release.

B&L launched Retisert (fluocinolone acetonide intravitreal implant) 0.59 mg in the U.S. market in July 2005. B&L said in its release it would remain responsible for Retisert marketing and product strategy.

“Novartis has an extensive physician-specialist network in place for its Visudyne (verteporfin for injection) therapy for the predominantly classic wet form of age-related macular degeneration, and we believe both companies can benefit from the synergies inherent in this co-promotion agreement for Retisert,” said Michael J. O’Rourke, vice president and general manager of B&L’s U.S. pharmaceuticals business.

Details of the agreement remain confidential, the release said.